Study finds investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes and impaired kidney function
Study finds investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes and impaired kidney function
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Jardiance | Research | Study | Urology & Nephrology